British Journal of Cancer

Article	Citations
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	159
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	137
Advancing radiomics from contrast-enhanced mammography in breast cancer	131
CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles	131
Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients	130
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours	125
Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach	124
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	120
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	97
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	94
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma	92
Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort	91
Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment	91
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	90
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	87
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	86
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	82
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis	81
Metastasis-associated fibroblasts in peritoneal surface malignancies	80
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	78
Statin use and survival among women with ovarian cancer: an Australian national data-linkage study	77
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours	77
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	74
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	74
Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US	74

Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	73
Metabolic adaptations in prostate cancer	72
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	71
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	71
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	71
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	71
Navigating therapeutic strategies: HPV classification in head and neck cancer	71
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	69
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	66
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3	65
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	64
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	63
Genomic ALK alterations in primary and relapsed neuroblastoma	63
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer	61
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	61
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	58
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	58
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	57
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	57
Identification of increased dedifferentiation along the Prom1+ cancer cells in Müllerian adenosarcoma with sarcomatous overgrowth	56
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	56
Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England	56
Hypoxia- and Postirradiation reoxygenation-induced HMHA1/ARHGAP45 expression contributes to cancer cell invasion in a HIF-dependent manner	53
Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma	53
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme	53
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	52
The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England	52
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials	52
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination	52
Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors	52
Emerging nanomedical strategies for direct targeting of pediatric and adult diffuse gliomas	52
Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma	51
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer	50
Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study	50
Progress and priorities in reducing the time to cancer diagnosis	49
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer	49
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors	48
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer	48
Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer	48
Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study	48
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II st	47
Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20	47
Optimizing adjuvant treatment strategies for non-pancreatic periampullary cancers	46
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification	46
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer	46
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia	46
Serum 25-hydroxyvitamin D concentrations and colorectal cancer incidence in adults with type 2 diabetes	46
Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England	46
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy	46
Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial	43

A systematic review of microbial markers for risk prediction of colorectal neoplasia	42
The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer	42
Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer	41
Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic	41
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers	41
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)	41
PTBP1 drives c-Myc-dependent gastric cancer progression and stemness	41
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer	41
Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma	41
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150	40
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer	40
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study	40
Cancer in Costello syndrome: a systematic review and meta-analysis	40
Multistate models for the natural history of cancer progression	39
Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients	39
Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications	39
Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma	39
Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28	38
Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis	38
Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer	38
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients	38
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia	38
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial	37
Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case–control study	37
A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses’ Health Studies	37
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients	36
Correction: Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes	36
Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer	35
High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade	35
Cancer risk in individuals with polydactyly: a Swedish population-based cohort study	35
Confidence bands in survival analysis	35
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions	35
Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8+ T cell infiltration	34
Thinking inside the box: intracellular roles for complement system proteins come into focus	34
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers	34
Manassantin A inhibits tumour growth under hypoxia through the activation of chaperone-mediated autophagy by modulating Hsp90 activity	34
Correction: Modelled mortality benefits of multi-cancer early detection screening in England	34
Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions	34
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study	34
MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling	33
Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer	33
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer	33
APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation	33
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer	33
Correction: Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	33
The in vitro dynamics of pseudo-vascular network formation	32
Consultations for clinical features of possible cancer and associated urgent referrals before and during the COVID-19 pandemic: an observational cohort study from English primary care	32
Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality	32
Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases	32
Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England	32
Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin	32
Immune checkpoint inhibitor combinations—current and emerging strategies	32
Oesophageal cancer awareness and anticipated time to help-seeking: results from a population-based survey	32
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis	32
What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study	32
50 years on and still very much alive: ‘Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics’	32
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors	31
A multimodal imaging study to highlight elastin-derived peptide pro-tumoral effect in a pancreatic xenograft model	31
Glycometabolic reprogramming-mediated proangiogenic phenotype enhancement of cancer-associated fibroblasts in oral squamous cell carcinoma: role of PGC-1α/PFKFB3 axis	31
Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma	31
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours	31
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer	31
Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets	31
Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial	31
Sodium nitrite orchestrates macrophage mimicry of tongue squamous carcinoma cells to drive lymphatic metastasis	30
The role of genetic predisposition in cardiovascular risk after cancer diagnosis: a matched cohort study of the UK Biobank	30
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial	30
The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review	30
The mediating role of combined lifestyle factors on the relationship between education and gastric cancer in the Stomach cancer Pooling (StoP) Project	30
DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance	30
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis	30
UK Biobank: a globally important resource for cancer research	30
Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer	30
Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer	30
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer	30
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations	29
VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models	29
Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer	29
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma	29
Health benefits and harms of mammography screening in older women (75+ years)—a systematic review	29

HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway	29
Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer	29
Regulatory non-coding somatic mutations as drivers of neuroblastoma	29
Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation	29
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status	29
Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer	29
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer	29
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study	29
Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility	29
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care	29
EIF4A3-negatively driven circular RNA β-catenin (circβ-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis	29
Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination	29
Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer	28
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma	28
Exploiting lipotoxicity for the treatment of liver cancer	28
MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data	28
Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study	28
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing	28
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function	28
Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune microenvironment in colorectal cancer	28
Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology	27
A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers	27
Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome	27
Obituary – Margaret Wilcox	27
BRCA-mutant pancreatic ductal adenocarcinoma	27
Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up	27
Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling	27
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?	27
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)	27
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer	27
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk	27
Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	27
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group	27
Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC	27
ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer	26
Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel–Lindau gene in the ccRCC	26
Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090)	26
Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition	26
Role of 18F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?	26
Correction: DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer	26
The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research	26
Prognostic value of post-operative iron biomarkers in colorectal cancer: population-based patient cohort	26
Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records	26
Associations between serum glucose, insulin, insulin resistance and the risk of incident primary liver cancer or chronic liver disease mortality: a nested case–control study	26
Editorial Expression of Concern: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential	26
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients	26
Understanding genetic architecture of breast cancer: how can proteome-wide association studies contribute?	26
Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis	26
Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer	25
Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study	25
Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma	25
Hypoxia-inducible factor 3α1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis	25
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer	25
Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration	25
Modelled mortality benefits of multi-cancer early detection screening in England	25
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies	25
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers	25
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis	24
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine	24
The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance	24
Comment on: “Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial”	24
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2	24
Angiogenin and plexin-B2 axis promotes glioblastoma progression by enhancing invasion, vascular association, proliferation and survival	24
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma	24
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy	24
Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study	24
Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer	24
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells	24
Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer	24
Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase	24
Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening	24
Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer	23
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer	23
HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3	23
Breast density is strongly associated with multiparametric magnetic resonance imaging biomarkers and pro-tumorigenic proteins in situ	23
The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study	23
Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential	23
Intratumour heterogeneity, from hypothesis to the clinic	23
Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus	23
Publisher Correction: Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study	23
Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis	23
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers	22
Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial	22
A liquid biopsy signature for predicting early recurrence in patients with gastric cancer	22
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial	22
Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC	22
Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study	22
LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis	22
Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer	22
Evolving roles of CD38 metabolism in solid tumour microenvironment	22
Benzaldehyde suppresses epithelial-mesenchymal plasticity and overcomes treatment resistance in cancer by targeting the interaction of 14-3-3ζ with H3S28ph	22
Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical features	22
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION	22
Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer	22
The epigenetic basis of hepatocellular carcinoma – mechanisms and potential directions for biomarkers and therapeutics	22